High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers

Umemura,Shinobu; Shirane,Masatoshi; Takekoshi,Susumu; Tokuda,Yutaka; Mori,Kazushige; Osamura,Robert Y.

doi:10.3892/ol_00000046

High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers

Authors:
- Shinobu Umemura
- Masatoshi Shirane
- Susumu Takekoshi
- Yutaka Tokuda
- Kazushige Mori
- Robert Y. Osamura
View Affiliations

Affiliations: Department of Pathology, Tokai University School of Medicine, Kanagawa 259-1193, Japan
Published online on: March 1, 2010 https://doi.org/10.3892/ol_00000046
Pages: 261-266

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of the estrogen receptor (ER), the progesterone receptor (PgR) or the human epidermal growth factor receptor-2 (HER2) in tumors is a good prognostic marker for breast cancer patients. However, approximately 15-20% of breast cancer patients have triple-negative breast cancer (TNBC; negative for ER, PgR and HER2), and efficient therapeutic modalities for these patients are under investigation. We focused on thymidine phosphorylase (TP), an enzyme metabolizing 5'-DFUR, an intermediate of capecitabine, to 5-fluorouracil in order to investigate the application of well-known therapeutics for TNBC. Results of a gene expression analysis showed that TP expression in TNBC and basal-like breast cancer (BLBC) was higher than that of other subtypes. Immunohistochemically, the high expression of TP in TNBC and BLBC reflected expression in stromal but not tumor cells. Notably, a high TP expression was observed in the stromal cells of EGFR- and/or CK5/6-positive breast tumors. Our present results showing a high expression of TP in BLBC indicate that capecitabine-based chemotherapy would be of benefit for patients with TNBC.

View Figures

View References

1	Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Panel members: Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 22009. Ann Oncol. 20:1319–1329. 2009. View Article : Google Scholar
2	Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365:1687–1717. 2005.PubMed/NCBI
3	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
4	Van’t Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530–536. 2002.PubMed/NCBI
5	Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
6	Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
7	Rakha EA, El-Sayed ME, Green AR, et al: Prognostic markers in triple-negative breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
8	Blum JL: Xeloda in the treatment of metastatic breast cancer. Oncology. 57(Suppl 1): 16–20. 1999. View Article : Google Scholar
9	Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 34:1274–1281. 1998. View Article : Google Scholar
10	Fiedkin M and Roberts D: The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J Biol Chem. 207:245–256. 1954.PubMed/NCBI
11	Moghaddam A and Bicknell R: Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry. 31:12141–12146. 1992. View Article : Google Scholar : PubMed/NCBI
12	Toi M, Atiqur Rahman M, Bando H, et al: Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 6:158–166. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between the efficacy of capecitabine and doxifluridine and the ration of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 58:685–690. 1998.
14	Sawada Y, Fujii T, Takahashi H, et al: A case of triple negative chest wall recurrent breast cancer treated with capecitabine and docetaxel combination therapy (XT therapy). Gan To Kagaku Ryoho. 36:815–817. 2009.PubMed/NCBI
15	Hachisuka Y, Kamei Y, Umeoka T, et al: A case of triple negative recurrent breast cancer successfully treated with capecitabine + docetaxel combination chemotherapy. Gan To Kagaku Ryoho. 35:475–458. 2008.PubMed/NCBI
16	Umemura S, Shirane M, Takekoshi S, et al: Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Br J Cancer. 100:764–771. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kono T, Nishida M, Inagaki N, et al: Development and characterization of 1C6–203, a new monoclonal antibody specific to human thymidine phosphorylase. J Histochem Cytochem. 49:131–138. 2001.
18	Tsuda H, Akiyama F, Kurosumi M, et al: Reproducible immuno-histochemical criteria based on multiple raters’ judgments for expression of thymidine phosphorylase in breast cancer tissue. Breast Cancer Res Treat. 86:215–223. 2004.PubMed/NCBI
19	Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
20	Baselga J, Albanell J and Ruiz A: Phase II and tumor pharmaco-dynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 23:5323–5333. 2005. View Article : Google Scholar : PubMed/NCBI
21	Shiu KK, Tan DS and Reis-Filho JS: Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opin Ther Targets. 12:1123–1137. 2008.
22	Kim JB, Stein R and O’Hare MJ: Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol. 26:173–185. 2005. View Article : Google Scholar : PubMed/NCBI
23	Finak G, Bertos N, Pepin F, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 14:518–527. 2008. View Article : Google Scholar : PubMed/NCBI
24	Evrard A, Cuq P, Ciccolini J, et al: Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer. 80:1726–1733. 1999. View Article : Google Scholar
25	Kato Y, Matsukawa S, Muraoka R, et al: Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer. 75:506–511. 1997. View Article : Google Scholar : PubMed/NCBI
26	Eda H, Fujimoto K, Watanabe S, et al: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol. 32:333–338. 1993.PubMed/NCBI
27	Tripathy D: Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist. 12:375–389. 2007. View Article : Google Scholar : PubMed/NCBI
28	Fujimoto-Ouchi K, Sekiguchi F and Tanaka Y: Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol. 49:211–216. 2002.PubMed/NCBI
29	Mori K, Hasegawa M, Nishida M, et al: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol. 17:33–38. 2000.PubMed/NCBI